ACR appropriateness criteria nonsurgical treatment for non-small-cell lung cancer

Poor performance status or palliative intent

Kenneth E. Rosenzweig, Joe Yujiao Chang, Indrin J. Chetty, Roy H. Decker, Mark E. Ginsburg, Larry L. Kestin, Feng Ming Kong, Brian E. Lally, Corey J. Langer, Benjamin Movsas, Gregory M.M. Videtic, Henning Willers

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Radiation therapy plays a potential curative role in the treatment of patients with non-small-cell lung cancer with locoregional disease who are not surgical candidates and a palliative role for patients with metastatic disease. Stereotactic body radiation therapy is a relatively new technique in patients with early-stage non-small-cell lung cancer. A trial from RTOG® reported >97% local control at 3 years. For patients with locally advanced disease, thoracic radiation to a dose of 60 Gy remains the standard of care. Sequential chemotherapy or radiation alone can be used for patients with poor performance status who cannot tolerate more aggressive approaches. Chemotherapy should be used for patients with metastatic disease. Radiation therapy is useful for palliation of symptomatic tumors, and a dose of approximately 30 Gy is commonly used. Endobronchial brachytherapy is useful for patients with symptomatic endobronchial tumors. The ACR Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances in which evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.

Original languageEnglish (US)
Pages (from-to)654-664
Number of pages11
JournalJournal of the American College of Radiology
Volume10
Issue number9
DOIs
StatePublished - Jan 1 2013

Fingerprint

Non-Small Cell Lung Carcinoma
Radiotherapy
Therapeutics
Thoracic Diseases
Guidelines
Radiation
Drug Therapy
Brachytherapy
Expert Testimony
Standard of Care
Neoplasms

Keywords

  • Appropriateness criteria
  • non-small-cell lung cancer
  • palliation
  • radiation therapy

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

ACR appropriateness criteria nonsurgical treatment for non-small-cell lung cancer : Poor performance status or palliative intent. / Rosenzweig, Kenneth E.; Chang, Joe Yujiao; Chetty, Indrin J.; Decker, Roy H.; Ginsburg, Mark E.; Kestin, Larry L.; Kong, Feng Ming; Lally, Brian E.; Langer, Corey J.; Movsas, Benjamin; Videtic, Gregory M.M.; Willers, Henning.

In: Journal of the American College of Radiology, Vol. 10, No. 9, 01.01.2013, p. 654-664.

Research output: Contribution to journalArticle

Rosenzweig, KE, Chang, JY, Chetty, IJ, Decker, RH, Ginsburg, ME, Kestin, LL, Kong, FM, Lally, BE, Langer, CJ, Movsas, B, Videtic, GMM & Willers, H 2013, 'ACR appropriateness criteria nonsurgical treatment for non-small-cell lung cancer: Poor performance status or palliative intent', Journal of the American College of Radiology, vol. 10, no. 9, pp. 654-664. https://doi.org/10.1016/j.jacr.2013.05.031
Rosenzweig, Kenneth E. ; Chang, Joe Yujiao ; Chetty, Indrin J. ; Decker, Roy H. ; Ginsburg, Mark E. ; Kestin, Larry L. ; Kong, Feng Ming ; Lally, Brian E. ; Langer, Corey J. ; Movsas, Benjamin ; Videtic, Gregory M.M. ; Willers, Henning. / ACR appropriateness criteria nonsurgical treatment for non-small-cell lung cancer : Poor performance status or palliative intent. In: Journal of the American College of Radiology. 2013 ; Vol. 10, No. 9. pp. 654-664.
@article{ae39e046199946569717d53124c7f33b,
title = "ACR appropriateness criteria nonsurgical treatment for non-small-cell lung cancer: Poor performance status or palliative intent",
abstract = "Radiation therapy plays a potential curative role in the treatment of patients with non-small-cell lung cancer with locoregional disease who are not surgical candidates and a palliative role for patients with metastatic disease. Stereotactic body radiation therapy is a relatively new technique in patients with early-stage non-small-cell lung cancer. A trial from RTOG{\circledR} reported >97{\%} local control at 3 years. For patients with locally advanced disease, thoracic radiation to a dose of 60 Gy remains the standard of care. Sequential chemotherapy or radiation alone can be used for patients with poor performance status who cannot tolerate more aggressive approaches. Chemotherapy should be used for patients with metastatic disease. Radiation therapy is useful for palliation of symptomatic tumors, and a dose of approximately 30 Gy is commonly used. Endobronchial brachytherapy is useful for patients with symptomatic endobronchial tumors. The ACR Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances in which evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.",
keywords = "Appropriateness criteria, non-small-cell lung cancer, palliation, radiation therapy",
author = "Rosenzweig, {Kenneth E.} and Chang, {Joe Yujiao} and Chetty, {Indrin J.} and Decker, {Roy H.} and Ginsburg, {Mark E.} and Kestin, {Larry L.} and Kong, {Feng Ming} and Lally, {Brian E.} and Langer, {Corey J.} and Benjamin Movsas and Videtic, {Gregory M.M.} and Henning Willers",
year = "2013",
month = "1",
day = "1",
doi = "10.1016/j.jacr.2013.05.031",
language = "English (US)",
volume = "10",
pages = "654--664",
journal = "Journal of the American College of Radiology",
issn = "1558-349X",
publisher = "Elsevier BV",
number = "9",

}

TY - JOUR

T1 - ACR appropriateness criteria nonsurgical treatment for non-small-cell lung cancer

T2 - Poor performance status or palliative intent

AU - Rosenzweig, Kenneth E.

AU - Chang, Joe Yujiao

AU - Chetty, Indrin J.

AU - Decker, Roy H.

AU - Ginsburg, Mark E.

AU - Kestin, Larry L.

AU - Kong, Feng Ming

AU - Lally, Brian E.

AU - Langer, Corey J.

AU - Movsas, Benjamin

AU - Videtic, Gregory M.M.

AU - Willers, Henning

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Radiation therapy plays a potential curative role in the treatment of patients with non-small-cell lung cancer with locoregional disease who are not surgical candidates and a palliative role for patients with metastatic disease. Stereotactic body radiation therapy is a relatively new technique in patients with early-stage non-small-cell lung cancer. A trial from RTOG® reported >97% local control at 3 years. For patients with locally advanced disease, thoracic radiation to a dose of 60 Gy remains the standard of care. Sequential chemotherapy or radiation alone can be used for patients with poor performance status who cannot tolerate more aggressive approaches. Chemotherapy should be used for patients with metastatic disease. Radiation therapy is useful for palliation of symptomatic tumors, and a dose of approximately 30 Gy is commonly used. Endobronchial brachytherapy is useful for patients with symptomatic endobronchial tumors. The ACR Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances in which evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.

AB - Radiation therapy plays a potential curative role in the treatment of patients with non-small-cell lung cancer with locoregional disease who are not surgical candidates and a palliative role for patients with metastatic disease. Stereotactic body radiation therapy is a relatively new technique in patients with early-stage non-small-cell lung cancer. A trial from RTOG® reported >97% local control at 3 years. For patients with locally advanced disease, thoracic radiation to a dose of 60 Gy remains the standard of care. Sequential chemotherapy or radiation alone can be used for patients with poor performance status who cannot tolerate more aggressive approaches. Chemotherapy should be used for patients with metastatic disease. Radiation therapy is useful for palliation of symptomatic tumors, and a dose of approximately 30 Gy is commonly used. Endobronchial brachytherapy is useful for patients with symptomatic endobronchial tumors. The ACR Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances in which evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.

KW - Appropriateness criteria

KW - non-small-cell lung cancer

KW - palliation

KW - radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=84883552147&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883552147&partnerID=8YFLogxK

U2 - 10.1016/j.jacr.2013.05.031

DO - 10.1016/j.jacr.2013.05.031

M3 - Article

VL - 10

SP - 654

EP - 664

JO - Journal of the American College of Radiology

JF - Journal of the American College of Radiology

SN - 1558-349X

IS - 9

ER -